| Autor: |
de Souza Filho, J. P., Correa, Z. M. S., Marshall, J. C., Anteka, E., Coutinho, A. B., Martins, M. C., Burnier Jr., M. N. |
| Předmět: |
|
| Zdroj: |
Eye; May2006, Vol. 20 Issue 5, p598-601, 4p, 1 Diagram, 1 Graph |
| Abstrakt: |
PurposeTo examine the effect of nepafenac, a selective cyclooxygenase-2 (COX-2) inhibitor, on the proliferation rate of two human retinoblastoma (Rb)cell lines.MethodsTwo human Rb cell lines (WERI-RB and Y79) were cultured. COX-2 expression in these cell lines was verified by imunocytochemical analysis of cytospin sections and Western blotting. An MTT-based proliferation assay was used to compare Rb cell growth with and without amfenac, the active metabolite of nepafenac. The averaged results per condition were recorded. The Student's t-test was used to compare results from the cells cultured with and without amfenac.ResultThe Y79 cell line showed a higher proliferative rate than the WERI-RB cell line. Both cell lines were negative for COX-2 expression by immunocytochemical analysis; however, both cell lines were positive for COX-2 expression by Western blot. When amfenac was added to both of the cell lines, a statistically significant reduction in proliferation was observed in both cell lines. The two Rb cell lines were positive for COX-2 only in the Western blot, indicating that they probably express low levels of COX-2, which was undetectable by immucytochemical analysis.ConclusionThe selective, anti-COX-2 molecule amfenac inhibited proliferation of both tested Rb cell lines. Further trials should be undertaken to study the effect of selective COX-2 inhibitors on Rb.Eye (2006) 20, 598–601. doi:10.1038/sj.eye.6701938; published online 17 June 2005 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
